- Home
- NCL vs IMRN Comparison
NCL vs IMRN Comparison
Compare NCL & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- IMRN
- Stock Information
- Founded
- NCL 2013
- IMRN 1994
- Country
- NCL United States
- IMRN Australia
- Employees
- NCL N/A
- IMRN N/A
- Industry
- NCL
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- IMRN Health Care
- Exchange
- NCL Nasdaq
- IMRN Nasdaq
- Market Cap
- NCL 13.1M
- IMRN 14.4M
- IPO Year
- NCL 2023
- IMRN N/A
- Fundamental
- Price
- NCL $0.42
- IMRN $1.59
- Analyst Decision
- NCL
- IMRN
- Analyst Count
- NCL 0
- IMRN 0
- Target Price
- NCL N/A
- IMRN N/A
- AVG Volume (30 Days)
- NCL 109.5K
- IMRN 386.0K
- Earning Date
- NCL 11-19-2025
- IMRN 08-29-2025
- Dividend Yield
- NCL N/A
- IMRN N/A
- EPS Growth
- NCL N/A
- IMRN N/A
- EPS
- NCL N/A
- IMRN N/A
- Revenue
- NCL $12,997,205.00
- IMRN $4,777,422.00
- Revenue This Year
- NCL N/A
- IMRN N/A
- Revenue Next Year
- NCL N/A
- IMRN N/A
- P/E Ratio
- NCL N/A
- IMRN N/A
- Revenue Growth
- NCL N/A
- IMRN 48.63
- 52 Week Low
- NCL $0.41
- IMRN $1.42
- 52 Week High
- NCL $12.16
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- NCL 42.68
- IMRN 33.82
- Support Level
- NCL $0.41
- IMRN $1.54
- Resistance Level
- NCL $0.50
- IMRN $1.67
- Average True Range (ATR)
- NCL 0.04
- IMRN 0.13
- MACD
- NCL -0.03
- IMRN -0.03
- Stochastic Oscillator
- NCL 4.37
- IMRN 19.74
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.